Suicidality and risk of suicide - Definition, drug safety concerns, and a necessary target for drug development: A brief report

Journal of Clinical Psychiatry

Volumn 71, Issue 8, 2010, Pages 1040-1046

  Meyer, Roger E ^a   Salzman, Carl ^b   Youngstrom, Eric A ^c   Clayton, Paula J ^d   Goodwin, Frederick K ^a,e   Mann, J John ^k   Alphs, Larry D ^f   Broich, Karl ^g   Goodman, Wayne K ^h   Greden, John F ⁱ   Meltzer, Herbert Y ^j   Normand, Sharon Lise T ^b   Posner, Kelly ^k   Shaffer, David ^k   Oquendo, Maria A ^k   Stanley, Barbara ^k   Trivedi, Madhukar H ^l   Turecki, Gustavo ^m   Beasley Jr , Charles M ⁿ   Beautrais, Annette L ^o,p   Bridge, Jeffrey A ^q   Brown, Gregory K ^r   Revicki, Dennis A ^s   Ryan, Neal D ^t   Sheehan, David V ^u   more..

^a Best Practice Project Management Inc   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d American Foundation for Suicide Prevention   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f Ortho McNeil Pharmaceutical Incorporated   (United States)

^g FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^k NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^l UNIVERSITY OF TEXAS AT DALLAS   (United States)

^m MCGILL UNIVERSITY   (Canada)

ⁿ ELI LILLY AND COMPANY   (United States)

^o YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF OTAGO   (New Zealand)

^q NATIONWIDE CHILDREN S HOSPITAL   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s UNITED BIOSOURCE CORPORATION   (United States)

^t UNIVERSITY OF PITTSBURGH   (United States)

^u UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGE DISTRIBUTION; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DEPRESSION; DRUG DEVELOPMENT; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; MEDICAL ETHICS; MENTAL DISEASE; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PSYCHOMETRY; RISK FACTOR; SEIZURE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; CAUSE OF DEATH; CHILD; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DRUG DISCOVERY; DRUG TOXICITY; HUMANS; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SUICIDE; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77955998262     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10cs06070ablu     Document Type: Article

References (39)

1. Committee on Pathophysiology and Prevention of Adolescent and Adult Suicide and Board on Neuroscience and Behavioral Health. Goldsmith SK, Pellmar TC, Kleinman AM, et al, eds. Reducing Suicide: A National Imperative. Washington, DC: National Academies Press; 2002.
2. Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396.
3. Christman DS, Faubion MD. Suicide attempt following initiation of topiramate [letter]. Am J Psychiatry. 2007;164(4):682-683.
4. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3): 332-339.
5. Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA. 2008;299(10):1121-1122.
6. Kalinin VV. Suicidality and antiepileptic drugs: is there a link? Drug Saf. 2007;30(2):123-142.
7. Sorensen HT, Mellemkjaer L, Olsen JH. Risk of suicide in users of beta-adrenoceptor blockers, calcium channel blockers and angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2001;52(3):313-318.
8. Stone M, Laughren T, Jones ML, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.
9. Katz LY. Concerns about health care warnings and their impact on prescribing behaviour. CMAJ. 2008;179(5):405-406.
10. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356-1363.doi:10.176/api.ajp.207. 07030454 PubMed (Pubitemid 47461135)
11. US Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality. August 16, 2004. http://www.fda.gov/ohrms/dockets/ac/ 04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf. Accessed January 10, 2009.
12. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164(7):1035-1043.
13. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Arch Gen Psychiatry. 2006;63(8):865-872.
14. Gray D, Achilles J, Keller T, et al. Utah Youth Suicide Study, phase I: government agency contact before death. J Am Acad Child Adolesc Psychiatry. 2002;41(4):427-434.doi:10.1097/04583-202040-015 PubMed (Pubitemid 38327919)
15. Søndergård L, Kvist K, Andersen PK, et al. Do antidepressants precipitate youth suicide?: a nationwide pharmacoepidemiological study. Eur Child Adolesc Psychiatry. 2006;15(4):232-240.
16. Leon AC, Marzuk PM, Tardiff K, et al. Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. J Clin Psychiatry. 2004;65(7):915-918.
17. Olfson M, Shaffer D, Marcus SC, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003;60(10):978-982.
18. Carlsten A, Waern M, Ekedahl A, et al. Antidepressant medication and suicide in Sweden. Pharmacoepidemiol Drug Saf. 2001;10(6):525-530.
19. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005;62(2):165-172.doi:10.101/archpsyc.62.2.165 PubMed (Pubitemid 40189132)
20. Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991-2000: trend analysis. BMJ. 2003;326(7397):1008.
21. Isacsson G. Suicide prevention - a medical breakthrough? Acta Psychiatr Scand. 2000;102(2):113-117.
22. Isacsson G, Bergman U, Rich CL. Epidemiological data suggest antidepressants reduce suicide risk among depressives. J Affect Disord. 1996; 41(1):1-8.doi:10.1016/0165-0327(96)050-X PubMed (Pubitemid 26364970)
23. Ludwig J, Marcotte DE. Anti-depressants, suicide, and drug regulation. J Policy Anal Manage. 2005;24(2):249-272.
24. Morgan OW, Griffiths C, Majeed A. Association between mortality from suicide in England and antidepressant prescribing: an ecological study. BMC Public Health. 2004;4(1):63.
25. Ohberg A, Vuori E, Klaukka T, et al. Antidepressants and suicide mortality. J Affect Disord. 1998;50(2-3):225-233.
26. Gould MS, Greenberg T, Velting DM, et al. Youth suicide risk and preventive interventions: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry. 2003;42(4):386-405.
27. Centers for Disease Control and Prevention (CDC). Suicide trends among youths and young adults aged 10-24 years - United States, 1990-2004. MMWR Morb Mortal Wkly Rep. 2007;56(35):905-908.
28. Bridge JA, Greenhouse JB, Weldon AH, et al. Suicide trends among youths aged 10 to 19 years in the United States, 1996-2005. JAMA. 2008;300(9):1025- 1026.
29. United States Department of Health & Human Services Food and Drug Administration. FDA Advisory: Suicidality and Antiepileptic Drugs. http://www.fda.gov/cder/drug/Infopage/antiepileptics/default.htm. Accessed 2008.
30. Jokinen J, Carlborg A, Mårtensson B, et al. DST non-suppression predicts suicide after attempted suicide. Psychiatry Res. 2007;150(3):297-303. doi:10.1016/j.psychres.206.12.01 PubMed (Pubitemid 46466966)
31. Jokinen J, Nordström P. HPA axis hyperactivity and attempted suicide in young adult mood disorder inpatients. J Affect Disord. 2009;116 (1-2):117-120.
32. Appleton KM, Rogers PJ, Ness AR. Is there a role for n-3 long-chain polyunsaturated fatty acids in the regulation of mood and behaviour? a review of the evidence to date from epidemiological studies, clinical studies and intervention trials. Nutr Res Rev. 2008;21(1):13-41.
33. Sublette ME, Milak MS, Hibbeln JR, et al. Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression. Prostaglandins Leukot Essent Fatty Acids. 2009;80(1):57-64.
34. Lalovic A, Levy E, Canetti L, et al. Fatty acid composition in postmortem brains of people who completed suicide. J Psychiatry Neurosci. 2007;32(5):363-370.
35. Lalovic A, Levy E, Luheshi G, et al. Cholesterol content in brains of suicide completers. Int J Neuropsychopharmacol. 2007;10(2):159-166.doi:10.1017/ S146145706063 PubMed (Pubitemid 46270991)
36. Trivedi MH, Rush AJ, Wisniewski SR, et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
37. Meltzer HY, Alphs L, Green AI, et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91.
38. Stanley B, Brown G, Brent DA, et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry. 2009;48(10):1005-1013.
39. Oquendo MA, Stanley B, Ellis SP, et al. Protection of human subjects in intervention research for suicidal behavior. Am J Psychiatry. 2004;161(9):1558-1563. (Pubitemid 39201450)